New York State Common Retirement Fund
BOLD

New York State Common Retirement Fund’s Audentes Therapeutics, Inc BOLD Stock Holding History

New York State Common Retirement Fund’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-40,400
Closed -$2.42M – 3220
2019
Q4 		$2.42M Sell
40,400
-7,900
-16% -$297K ﹤0.01% 1548
2019
Q3 		$1.36M Buy
48,300
+3,300
+7% +$113K ﹤0.01% 1838
2019
Q2 		$1.7M Buy
45,000
+7,600
+20% +$292K ﹤0.01% 1735
2019
Q1 		$1.46M Buy
37,400
+5,800
+18% +$166K ﹤0.01% 1768
2018
Q4 		$674K Sell
31,600
-4,100
-11% -$106K ﹤0.01% 2133
2018
Q3 		$1.41M Hold
35,700
– – ﹤0.01% 1893
2018
Q2 		$1.36M Buy
35,700
+13,500
+61% +$500K ﹤0.01% 1921
2018
Q1 		$667K Buy
22,200
+5,800
+35% +$196K ﹤0.01% 2229
2017
Q4 		$513K Hold
16,400
– – ﹤0.01% 2344
2017
Q3 		$459K Hold
16,400
– – ﹤0.01% 2397
2017
Q2 		$314K Buy
16,400
+12,299
+300% +$196K ﹤0.01% 2644
2017
Q1 		$70K Buy
4,101
+2,201
+116% +$35.6K ﹤0.01% 3022
2016
Q4 		$35K Buy
+1,900
New +$32.8K ﹤0.01% 3085

New York State Common Retirement Fund's BOLD Position: Q1 2020 in Review

New York State Common Retirement Fund sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 40,400 shares — an estimated $2.42M sold.

New York State Common Retirement Fund first reported a position in BOLD in Q4 2016 and held it in 13 quarters. The position peaked at $2.42M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

  • New York State Common Retirement Fund reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
  • New York State Common Retirement Fund sold 40,400 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $2.42M.
  • New York State Common Retirement Fund first reported a position in Audentes Therapeutics, Inc in Q4 2016 and held it in 13 quarters.
  • New York State Common Retirement Fund's Audentes Therapeutics, Inc position peaked at $2.42M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on New York State Common Retirement Fund's 13F filing for Q1 2020, filed 6 May 2020.